U.S. In-Vitro Diagnostics Market

U.S. In-Vitro Diagnostics Market Overview

The U.S. In-Vitro Diagnostics Market size was valued at USD 25.54 billion in 2023, and is predicted to reach USD 32 billion by 2030, at a CAGR of 2.9% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. These tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology. 

IVD tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics. Also, immunoassay experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Rising Chronic Disease Prevalence Drives the U.S. In-Vitro Diagnostics Market Growth

The prevalence of chronic diseases serves as a significant growth driver for the in-vitro diagnostics market in the U.S. Chronic conditions such as diabetes, cardiovascular diseases, and cancer are increasingly common among the population, leading to a heightened demand for diagnostic tests. 

Early detection and ongoing monitoring of these diseases are crucial for effective management and treatment. The National association of Chronic Disease Directors reported that cardiovascular diseases accounts for one out of every three deaths in the U.S., totalling 859,000 deaths every year. In response to this, the demand for IVD is rising, facilitating diagnosis, monitoring, and management of chronic diseases in this country.

Presence of Leading Companies Drive the Expansion of the Market

The presence of prominent companies including Bio-Rad Laboratories Inc, Becton, Dickinson and Company, Abbott Laboratories, Quest Diagnostics, and others are involved in innovation, R&D activities, and collaborations which in turn foster the U.S. in-vitro diagnostics market growth. 

For instance, in January 2023, Bio-Rad Laboratories Inc recently introduced the CFX Opus 96 Dx Real-Time PCR System, marking its entry into the In-Vitro diagnostic testing arena. The product is approved by the U.S. Food and Drug Administration (FDA) for In-Vitro diagnostic testing and compliant with European Union regulations for In-Vitro diagnostic medical devices. 

Bio-Rad's CFX Opus 96 Dx PCR System boasts a user-friendly interface and intuitive software, facilitating seamless operation and minimizing training requirements for lab staff. Its adaptable nature, accommodating various assay formats, offers laboratories the flexibility to employ their preferred testing protocols, provides precise and prompt diagnostic outcomes, thereby enhancing patient care and overall outcomes.

High Research, Development, and Regulatory Approval Costs Hinder the Market Growth

High costs associated with research, development, and regulatory approval are significant factors restraining the U.S. in-vitro diagnostics market expansion. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development. 

This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability. Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.

Introduction of Point-of-Care Testing Solutions in IVD Creates Market Opportunities

Point-of-care testing (POCT) is poised to be a significant driver of in the U.S. IVD market demand, in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings. 

With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions. 

By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

Competitive Landscape

The promising players operating in the U.S. in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

U.S. In-Vitro Diagnostics Market Key Segments

By Product & Service                

• Reagents & Consumables            

  • Clinical Chemistry Reagents        

  • Immunoassay Reagents (ELISA/CLIA)        

  • Molecular Master Mixes        

  • Hematology Controls        

• Instruments & Devices            

  • Chemistry Analyzers        

  • Immunoassay Systems        

  • Molecular Thermocyclers/Sequencers        

  • Hematology Analyzers        

  • POC Devices        

• Software & Services            

  • LIS, Data Analytics        

  • CRO/Testing Services        

By Technique                

• Clinical Chemistry            

  • Metabolites        

  • Electrolytes        

  • Enzymes        

• Immunoassays            

  • ELISA / CLIA / CMIA        

  • Lateral-flow Rapid Tests        

  • Immunofluorescence        

• Molecular Diagnostics            

  • PCR        

  • Isothermal NAAT        

  • NGS        

  • In-situ Hybridization        

• Hematology & Coagulation            

  • CBC Analyzers        

  • Coagulation Panels        

• Microbiology            

  • Culture & Sensitivity        

  • MALDI-TOF        

  • Molecular ID        

• Urinalysis & Body Fluids            

• Other Techniques            

By Testing Site / Channel                

• Central & Reference Laboratories            

• Hospital & Physician Labs            

• Point-of-Care & Retail            

• Home & Self-Testing            

By Application            

• Infectious Diseases            

• Oncology            

• Cardiovascular Health            

• Endocrinology & Diabetes            

• Nephrology            

• Genetic & Prenatal Testing            

• Autoimmune Disorders            

• Drug Monitoring & Toxicology            

• Blood Screening & Typing            

• Other Indications            

KEY PLAYERS

• Roche Holding AG

• Abbott Laboratories

• Thermo Fisher Scientific Inc.

• Danaher Corporation

• Becton, Dickinson and Company

• Siemens Healthineers AG

• bioMérieux SA

• Sysmex Corporation

• QIAGEN N.V.

• Bio-Rad Laboratories, Inc.

Report Scope and Segmentation